Clinical Next-Generation Sequencing in Sarcoma Diagnosis and Classification: A Real-World Cohort Study

Sarcomas are a rare and complex family of cancers that arise in the body's connective tissues, such as bone, muscle, fat, and cartilage. Unlike many other cancers that have a single, clear identity, sarcomas are a diverse group with over a hundred different subtypes. This variety creates a significant challenge for doctors: under a microscope, many of these tumors look strikingly similar, often sharing the same shapes and staining patterns, even though they behave very differently and require completely different treatments. For decades, pathologists have relied on visual clues and protein markers to sort these tumors, but when those clues overlap, the diagnosis can remain uncertain. In recent years, a powerful tool called next-generation sequencing has emerged to help solve this puzzle. This technology reads the genetic code of a tumor, looking for specific errors or rearrangements in the DNA that act as unique fingerprints for different types of cancer. By finding these molecular signatures, doctors can often identify the true nature of a tumor with much greater certainty than by looking at it alone.

A team of researchers at Nanjing Drum Tower Hospital recently put this approach to the test in a real-world setting, examining a group of 106 patients with suspected or confirmed bone and soft tissue tumors. They wanted to see how often clinical genetic sequencing could actually change the way these difficult cases were understood and treated. The study focused on patients who had already undergone standard testing but where the diagnosis remained unclear or where the tumor had returned after initial treatment. The researchers collected genetic data from these patients and compared the new molecular findings against the original diagnoses. They found that in more than half of the cases, the genetic testing provided crucial information that altered the medical understanding of the disease. Specifically, for 37 patients, the test either completely reclassified the tumor into a different category or refined a vague diagnosis into a specific one. For another 24 patients, the test confirmed the existing diagnosis with molecular proof. This means that for a significant portion of the cohort, the genetic test was the key that unlocked a precise identity for a tumor that was previously a mystery.

The power of this method was most evident in cases where the tumor looked like a generic, undifferentiated mass under the microscope. In the study, nearly all of the tumors that were initially labeled as "sarcoma, not otherwise specified" or "undifferentiated round cell sarcoma"—terms used when a doctor cannot pinpoint the exact type—were given a specific name after genetic analysis. One striking example involved a tumor that looked like a fibrosarcoma but was reclassified as a gastrointestinal stromal tumor, a type of cancer that responds well to a specific drug called imatinib. Another case involved a tumor that was thought to be a clear cell sarcoma but, after failing to show the expected genetic markers, was correctly identified as an undifferentiated pleomorphic sarcoma. These changes were not just academic; they directly influenced treatment choices. When a tumor is correctly identified, doctors can select therapies that target the specific weaknesses of that cancer type, rather than using a broad, less effective approach.

Beyond simply naming the tumors, the researchers mapped the genetic landscape of these cancers to see what made them tick. They discovered that sarcomas fall into two broad genetic categories. One group, known as translocation-associated sarcomas, is driven by a specific event where two genes swap pieces of their DNA, creating a fusion that drives the cancer. The other group, which includes many of the more complex and aggressive tumors, is characterized by a chaotic accumulation of many different genetic errors, such as missing chunks of DNA or extra copies of genes. The study confirmed that these two groups are fundamentally different: the complex tumors carried a much higher number of genetic alterations than the fusion-driven ones. This distinction helps explain why some sarcomas are harder to treat than others and suggests that different strategies are needed for each group. The researchers also found that the tumor mutational burden, a measure of how many random errors exist in the cancer's DNA, was generally low across the board, which is a known characteristic of adult soft tissue sarcomas.

The genetic testing also looked for specific fusion events, which are like broken zippers where two genes get stuck together. The researchers found these fusions in two-thirds of the patients who had their RNA, or genetic messenger, analyzed. They identified a new candidate fusion in a rare tumor called pleomorphic liposarcoma, where a gene called SFXN1 was fused with NRG2. This finding was supported by matching evidence from both the DNA and RNA levels, suggesting it is a real biological event rather than a mistake. Furthermore, the study highlighted that knowing which gene a fusion is attached to matters immensely. For instance, a gene called EWSR1 can fuse with several different partners. In this cohort, the researchers saw that EWSR1 fused with one partner in Ewing sarcoma, but with a different partner in clear cell sarcoma. Simply knowing that EWSR1 is involved is not enough; identifying the partner gene is what allows for a precise diagnosis.

Finally, the study tracked what happened when these genetic findings led to treatment. Out of the patients who had a genetic alteration that could be targeted by a drug, about one-third received a therapy matched to their specific mutation. The results were promising. Among those who were treated and could be evaluated, three patients saw their tumors shrink significantly, and six others saw their disease stabilize, meaning it stopped growing for a time. One patient with a reclassified gastrointestinal stromal tumor responded well to imatinib and remained free of disease progression for nearly 20 months. Another patient with a rare nerve sheath tumor saw a partial response to a drug designed to target a specific gene amplification. While not every patient with a targetable mutation received matched therapy—sometimes because standard treatments were still the best option or because the disease was too advanced—the study demonstrated that when the right genetic match was found, it could lead to tangible clinical benefits.

This research underscores that for sarcoma patients, especially those with difficult-to-diagnose tumors, genetic sequencing is becoming an essential part of the diagnostic toolkit. It does not replace the pathologist's eye but works alongside it to provide a clearer picture of the disease. By turning vague descriptions into specific molecular identities, these tests help doctors move away from a one-size-fits-all approach and toward precision medicine, where the treatment is tailored to the unique genetic makeup of the individual's cancer. The study confirms that while sarcomas are a diverse and challenging group of diseases, the genetic code holds the key to understanding them better and treating them more effectively.